To flip bullish in the current 2026 market cycle, Injective (INJ) must decisively reclaim and hold the 20-day Exponential Moving Average (EMA) as support. Recent data confirms another rejection at this critical technical level, signaling that the downward pressure remains the dominant force. This struggle is highlighted by on-chain metrics showing that the total supply in profit has flattened near $75 million, suggesting a lack of fresh buyer conviction necessary to absorb current sell orders.
The repeated failure at the 20-day EMA indicates a trend where short-term relief rallies are being used by traders to exit positions rather than build new ones. For US-based investors, this level serves as a primary pivot point; remaining below it typically precedes a test of deeper liquidity zones. The stagnation in profit metrics further implies that while long-term holders are not yet panicking, there is insufficient momentum to drive the asset into a new expansion phase.
This technical stagnation occurs as the broader DeFi sector navigates a complex regulatory landscape in 2026, with US authorities focusing heavily on decentralized exchange (DEX) protocols. While Injective’s underlying technology remains a leader in the sector, the macro-uncertainty surrounding high-speed trading chains has narrowed the path for a solo breakout. For INJ to decouple from the neutral sentiment of the wider altcoin market, it will need a significant fundamental catalyst to overcome its technical hurdles.
Investors should closely monitor the daily close relative to the 20-day EMA over the coming week. A sustained move above this line on high volume would likely invalidate the current bearish thesis and signal a run toward previous quarterly highs. Conversely, if the supply in profit remains flat and the EMA continues to act as a ceiling, the market should prepare for a potential retest of the support levels established at the start of the year.